Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy.
Basetti MadhuGreg L ShawAnne Y WarrenDavid E NealJohn R GriffithsPublished in: Metabolomics : Official journal of the Metabolomic Society (2016)
The reduced concentrations of lactate and t-choline metabolites due to Degarelix could in principle be monitored by in vivo 1H MRS, which suggests that it would be possible to monitor the effects of physical or chemical castration in patients by that non-invasive method.